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CASE REPORT Open Access
Circulating tumour DNA (ctDNA) as a
biomarker in metachronous melanoma and
colorectal cancer- a case report
Leslie Calapre1†, Lydia Warburton2*† , Michael Millward2,3 and Elin S. Gray4
Abstract
Background: Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring
disease status of patients with advanced cancers. The presence of ctDNA in the blood is a result of biological
processes, namely tumour cell apoptosis and/or necrosis, and can be used to monitor different cancers by targeting
cancer-specific mutation.
Case presentation: We present the case of a 67 year old Caucasian male that was initially treated with BRAF
inhibitors followed by anti-CTLA4 and then anti-PD1 immunotherapy for metastatic melanoma but later developed
colorectal cancer. The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R
(melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient’s tumours. In fact, the
discordant pattern of BRAF and KRAS ctDNA was significantly correlated with the clinical response of melanoma to
pembrolizumab treatment and progression of colorectal cancer noted by PET and/or CT scan. Based on these
results, ctDNA can be used to specifically clarify disease status of patients with metachronous cancers.
Conclusions: Using cancer-specific mutational targets, we report here for the first time the efficacy of ctDNA to
accurately provide a comprehensive outlook of the tumour status of two different cancers within one patient. Thus,
ctDNA analysis has a potential clinical utility to delineate clinical information in patients with multiple cancer types.
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Background
In recent years, tumour-derived cell free DNA (ctDNA)
has emerged as a promising biomarker of disease status
for metastatic cancer [1–3]. Plasma ctDNA are short nu-
cleic acid fragments (~ 166 bp) thought to be released in
the systemic circulation as a result of tumour cell apop-
tosis and/or necrosis [4, 5]. Previous studies have shown
that ctDNA carries genetic information from the entire
tumour genome and can therefore provide insights into
clonal heterogeneity and evolution of all solid cancers
present at any one time [6, 7]. As analysis of ctDNA can
be tailored for different cancers by targeting specific mu-
tations, it provides detailed information via a minimally
invasive ‘liquid biopsy’, eliminating the morbidity
associated with serial sampling of tumours for monitor-
ing patients with any advanced solid cancers.
Various studies in breast, lung and colorectal cancers
have demonstrated the potential clinical application of
ctDNA analysis at each stage of cancer management: early
diagnosis [5, 8], molecular profiling [6, 9–11], prognostica-
tion [5, 12, 13], detection of residual disease [14, 15], moni-
toring response and clonal evolution [16–20]. In
melanoma, several studies have also shown the efficacy of
utilising ctDNA for monitoring patients with BRAF mutant
tumours, particularly in the context of treatment response
and identification of mechanisms of resistance to BRAF in-
hibitors [7, 21–26]. These studies provide credence to the
utility of ctDNA for patient monitoring only in the context
of singular cancer. To date, ctDNA remains unutilised in
clinical management of patients with multiple tumour types
and/or those metachronous cancers where new primary tu-
mours arise that are unrelated to the original malignancy.
In this case study, we demonstrated the efficiency of ctDNA
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to delineate the different status of both melanoma and
colorectal cancers in a single patient.
Case presentation
A 67-year old male was investigated in our institution in
2012 for weight loss and abdominal pain. He was other-
wise fit and well, with no significant comorbid medical
history. He was not on any regular medications, had no
known allergies and had no significant family history.
Computed tomography (CT) revealed moderate ascites
and a large splenic mass. Fine needle splenic aspirate
was non-diagnostic and therefore a therapeutic/diagnos-
tic splenectomy was performed. Metastatic melanoma
was confirmed histologically, and further testing con-
firmed a BRAF V600R mutation via Sanger sequencing.
In July 2014, he commenced dabrafenib and trametinib
treatment for progressive disease but suffered unaccept-
able toxicity, which led to the cessation of the combined
targeted therapies.
At progression the patient was subsequently treated
with four doses of ipilimumab (3 mg/kg three weekly)
but was found to have disease progression on the first
response assessment CT scan. Confirmed progression
in lung metastases and the intra-abdominal nodal dis-
ease led to commencement of anti PD-1 therapy
(pembrolizumab 2 mg/kg three weekly) in March 2015
(week 2, Fig. 1). He completed 28 cycles (week 94) of
pembrolizumab and achieved a complete metabolic
response on PET at six months in all the previously
identified metastatic sites. He tolerated treatment well
with vitiligo as the sole side effect.
However, PET at 32 weeks identified a new FDG avid
lesion within the sigmoid colon. This was investigated
with colonoscopy and tissue biopsy confirmed a low
grade sigmoid adenocarcinoma. He proceeded to a sub-
total colectomy, ilio-sigmoid anastomosis and lymph
node dissection in January 2016 (week 46). Histopath-
ology confirmed a stage III (T4N1M0 AJCC 7th edition)
low grade sigmoid adenocarcinoma with 3/33 lymph
nodes involved. The tumour had no mismatch repair de-
ficiency. Molecular analysis using next generation se-
quencing via the Illumina Trusight tumour panel
showed the primary tumour to be KRAS p. G13D mu-
tant, NRAS and BRAF wild type. Post-operative CEA
measurements were negative.
Adjuvant chemotherapy for colon cancer was offered
but the patient decided to continue with pembrolizumab
for metastatic melanoma and declined chemotherapy. In
November 2016, eleven months after curative resection
of primary colorectal cancer, para-aortic nodes enlarged
Fig. 1 ctDNA analysis can discriminate the status of different tumours in a patient with both melanoma and colorectal cancer. Levels of BRAF and
KRAS ctDNA (green) inform of the status of melanoma and colon cancer respectively. Clinical partial response (PR) and complete response (CR)
annotations are indicative of melanoma response to pembrolizumab as measured by RECIST on CT imaging. PET scan images associated with
four different timepoints with differential BRAF and KRAS ctDNA levels
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marginally and became intensely FDG avid on PET des-
pite on-going pembrolizumab. Biopsy of an enlarging
para-aortic node at approximately week 88 confirmed
metastatic colorectal cancer. Molecular analysis of the
colorectal metastasis confirmed KRAS p. G13D muta-
tion. It is of note that the patient had no other sites of
disease progression and remained in complete response
from metastatic melanoma, which led to cessation of
pembrolizumab treatment.
The recurrence was unresectable and the patient was
offered palliative FOLFOX chemotherapy with bevacizu-
mab (B) but chose to undergo observation with three
monthly clinical and radiological reviews. His imaging
demonstrated RECIST (Response Evaluation Criteria in
Solid Tumours) stable disease for 18 months and he then
progressed with new liver and lung lesions. He has
recently commenced B-FOLFOX chemotherapy with re-
sponse assessment pending.
ctDNA screening and monitoring
In parallel to the imaging scans, the patient was moni-
tored for melanoma and colorectal cancer by tracking
BRAF p.V600R and KRAS p.G13D mutations in ctDNA
respectively. Blood samples were collected in EDTA and
Streck tubes. Plasma was separated within 24 h by cen-
trifugation at 300 g for 20 min, followed by a second
centrifugation at 4700 g for 10 min, and then stored at
-80 °C until extraction. Cell-free DNA (cfDNA) was
extracted from 5ml of plasma using the QIAamp Circu-
lating Nucleic Acid Kit (Qiagen) as per the manufac-
turer’s instructions. Analysis of plasma ctDNA was
carried out using an in-house BRAF p.V600R assays [27]
and a commercial KRAS p.G13D (Bio-Rad) for droplet
digital PCR (ddPCR). Protocols used for ddPCR analysis
were as previously described [21, 28] and ctDNA levels
were calculated based on the number of copies per milli-
litres of plasma (c/mL).
Plasma analysis demonstrated the presence of BRAF
V600R ctDNA at baseline prior to initiating pembrolizu-
mab, which became undetectable at subsequent follow-
up (weeks 2–10.) The patient achieved sustained partial
response to pembrolizumab (week 18–49) by CT and
complete metabolic response by PET scan, which was
supported by his corresponding ctDNA data (Fig. 1). As
predicted, the patient’s blood sample at the time of colo-
rectal cancer diagnosis (week 36) had detectable KRAS
mutant ctDNA (2 c/mL). Retrospective analysis of the
previous blood samples revealed detectable levels of
KRAS mutant ctDNA prior to immunotherapy (3 c/mL),
suggesting that colorectal cancer may have already been
present at the time of stage IV melanoma diagnosis.
Subsequent plasma samples (weeks 2–49) were also
found to have detectable KRAS mutant ctDNA, albeit at
consistently low levels that ranged from 2 to 4 c/ml,
with the exception of the blood sample collected at week
64 that was negative for ctDNA. In this case, real time
knowledge of detectable ctDNA following curative bowel
resection, implying residual microscopic disease, and the
negative BRAF mutant melanoma ctDNA may have
influenced and ultimately changed the clinician and pa-
tients decision from not having adjuvant chemotherapy,
to receiving it.
Increased KRAS mutant ctDNA was further observed at
week 70 (6 c/mL), which provided an early indication of
disease progression. Prior to the cessation of pembrolizu-
mab corresponding to the melanoma complete response,
KRAS mutant ctDNA levels was at its peak (14 c/mL). A
final ctDNA assessment at week 119, revealed that BRAF
V600R ctDNA continues to be undetectable which is con-
sistent with sustained complete response of melanoma.
Nevertheless, ctDNA for KRAS G13D remained high (7 c/
ml) suggesting possible radiologically undetectable pro-
gression of the patient’s untreated colon cancer.
Discussion and conclusion
This case study highlights the evolving role of ctDNA in
detecting metachronous cancers. Development of new
primary tumours that are unrelated to the original ma-
lignancy have become a significant adverse effect in
patients with metastatic cancers who achieved sustained
or durable disease control in response to targeted and/or
systemic therapy. Thus, oncologists should be vigilant to
the possibility that patients are at continued risk for new
and separate malignancies.
Previous studies have demonstrated the clinical utility
of ctDNA as a biomarker of disease status in patients
with metastatic cancers, particularly in the context of
singular tumour types. However, to date there has been
no report of the clinical utility of ctDNA to delineate
status of different tumour types within patients with
multiple cancers. In this case study, we demonstrated
the efficiency of ctDNA, by targeting tumour-specific
mutations to specifically inform treatment response and
tumour status in a patient with both melanoma and
colorectal cancer. Given the increased risk of cancer pa-
tients to develop other malignant tumours, this study
supports the potential clinical use of ctDNA for profiling
of other emerging lesions and identification of their ori-
gin. Plasma ctDNA may be useful for accurate stratifica-
tion of treatment response in patients with two or more
different tumour types, providing better perspective of
disease status for more informed treatment options. In
this setting, pan-cancer ctDNA testing can aid on the
early detection of metachronous cancers.
The low melanoma derived ctDNA at baseline may be
the result of partial disease control by the previous ipili-
mumab therapy, although not evident by the CT scan
performed. The immediate drop and undetectable levels
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of BRAF mutant ctDNA during pembrolizumab treat-
ment indicated the response of the patient’s melanoma
tumour to this treatment. On the other hand, colon can-
cer derived ctDNA (KRAS) was also detectable at base-
line, and given that it is at similar concentrations as
BRAF, the patient’s melanoma and colorectal tumour
burden may be relatively similar. Studies have shown
that ctDNA is readily detectable in early stages colon
cancer patients [29, 30] which may explain the detect-
ability of colon cancer ctDNA in this patient. Neverthe-
less, we like to note that we observed fluctuations of the
level of KRAS mutant ctDNA at the time of pembrolizu-
mab treatment. Interestingly, the KEYNOTE-164 clinical
trial has demonstrated durable anti-tumour activity of
pembrolizumab in colorectal cancer patients, particularly
those with high microsatellite instability (MSI) [31]. We
hypothesise that pembrolizumab may have exerted some
level of control on the colorectal tumour. However, fur-
ther investigation is needed, particularly identifying the
MSI status of the patient, to determine if he may have
benefited from pembrolizumab treatment. The variabil-
ity on detection of ctDNA across multiple cancers and
tumour locations, also remains a topic of investigation in
the field of liquid biopsy research.
In conclusion, ongoing close surveillance of melanoma
patients who achieved complete response to BRAF
inhibition and/or immune-checkpoint inhibitors is para-
mount to monitor potential recurrent disease. Emergent
of new malignant lesions in this population should be
regarded as a metastasis only after detailed evaluation,
including a biopsy where feasible; otherwise there is a
possibility of missing a secondary malignancy. Plasma
ctDNA may aid in clarifying disease status of patients
with metachronous cancer.
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